

## Research Activities Newsletter

---

July and August 2022

### In the News: Congratulations to the following awardees!!



**Rachael Hageman Blair**, Associate Professor of Biostatistics, is Co-I on a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH (PI: Chelsie Elizabeth Armbruster, Microbiology and Immunology) for the research project entitled, *Conserved Proteus Mirabilis Genetic Requirements for Colonization of the Catheterized Urinary Tract*. The study aims to uncover novel, conserved, and clinically relevant targets for therapeutic intervention of catheter-associated urinary tract infections, which are among the most common hospital-acquired infections worldwide.



**Akua Gyamerah**, Assistant Professor of Community Health and Health Behavior, is PI on a new K award from the National Institute of Mental Health/NIH for the project entitled, *Intersectional Minority Stress, Mental Health, and HIV Treatment and Care Among MSM Living with HIV in Ghana*. The study will integrate intersectionality and minority stress theory and operationalize measures to examine how intersectional social stressors affect mental health and HIV treatment outcomes among Ghanaian MSM living with HIV. A goal is to improve health by developing an intervention to mitigate factors on this pathway.



**Gregory Homish**, Professor and Chair of Community Health and Health Behavior, is PI on a continuation award from National Institute on Drug Abuse/NIH, for the project entitled, *Substance Use in Reservists: Social and Environmental Influences*. The longitudinal study is in its 10<sup>th</sup> year and continues to examine the impact of two military experiences - never being deployed and separation from military – on substance use outcomes for both soldiers and their spouses.



**David Hostler**, Professor and Chair of Exercise and Nutrition Sciences, is PI on a new award from Create Inc./Office of Naval Research for the research project entitled, *Physiological Monitoring to Accelerate Safe Decompression*. The project seeks to develop a wireless diver physiology monitor (WDPM), thereby eliminating wires of all sensors and circuits and encapsulating the batteries in a waterproof housing. The WDPM would allow for individualized decompression, minimizing the decompression obligation while monitoring and maintaining the safety of the diver.



**Katarzyna Kordas**, Associate Professor of Epidemiology and Environmental Health (EEH), is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the project entitled, *Effect of Complex Mixtures on Oxidative Stress and Cognition in Children*. The study will continue to examine the extent to which chemical mixtures in early-middle childhood affect a molecular process thought to underlie the development of chronic disease, as well as functional endpoints that underlie children's learning and social interactions. **Hailey Banack**, Research Assistant Professor of EEH, **James Olson**, UB Distinguished Professor of Pharmacology & Toxicology and EEH, and **Guan Yu**, Assistant Professor of Biostatistics, are Co-Is.



**Jessica Kruger**, Clinical Assistant Professor of Community Health and Health Behavior, and **Patricia Ohtake**, Associate Professor of Rehabilitation Science, are PIs on a new award from Western New York BloodCare for the project entitled, *Western New York BloodCare Interprofessional Student Education Fund*. The fund will support the development of three student-focused learning opportunities that elevate care for patients with non-malignant bleeding and clotting disorders.



**Dr. Kruger** also is Co-I on a new award from the Association of American Medical Colleges (PI: Alison Vargovich, Medicine) for the project entitled, *Mitigating Medical Misinformation and Mistrust through Effective Team Communication Developed Using Innovative Competency-based Interprofessional Instructional Design Strategies*. The award will establish an interprofessional educational experience for health professions students to develop skills in understanding medical misinformation, theory to understand the current stage of change, and strategies to communicate health information and dispel misinformation.



**Lucia Leone**, Associate Professor of Community Health and Health Behavior, is Co-I on a continuation award (PI: Stephanie Anzman-Frasco, Pediatrics) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH for the project entitled, *Promoting Healthier Meal Selection and Intake among Children in Restaurants*. The goal of the study is to establish the effectiveness of an in-restaurant intervention that is easy to implement and can be applied across restaurant contexts to promote healthier eating among children.



**Lindsey Mattick**, PhD candidate in the Department of Epidemiology and Environmental Health (EEH), is the PI and trainee on an F-31 continuation award from the National Institute of Aging/NIH entitled, *Follicle Stimulating Hormone and Bone Loss in Postmenopausal Women*. **Heather Ochs-Balcom**, Associate Professor in EEH and **Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor in EEH are her Faculty Sponsors. The study will explore the independent effects of estrogen and follicle stimulating hormone (FSH), which rises with menopause, on bone mineral density and fracture risk.



**Amy Millen**, Associate Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Eye Institute/NIH for the research project entitled, *A Study of Estrogen and Body Mass Index in Fuch's Endothelial Corneal Dystrophy*. Using data of postmenopausal women in the WHI, the study is examining associations between estrogen exposure, menopausal hormone therapy, body mass index, and serum estradiol concentrations in relation to Fuchs' endothelial corneal dystrophy, the leading cause of corneal blindness within the U.S. **Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor in EEH is Co-Investigator.



**Heather Ochs-Balcom**, Associate Professor of Epidemiology and Environmental Health (EEH), is MPI on a new award from Arizona Board of Regents/National Cancer Institute for the project entitled, *Role of FSH in Postmenopausal Obesity and Breast Cancer*. The study is the first comprehensive epidemiologic investigation of FSH and obesity to measure and study FSH levels in the years prior to breast cancer diagnosis to assess the potential role of FSH in breast cancer. The results will enable translation to more precise breast cancer prevention interventions. **Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor in EEH, is Co-Investigator.



**Heather Orom**, Associate Professor of Community Health and Health Behavior and Associate Dean for Equity, Diversity and Inclusion, is Co-I on a continuation award from the National Center for Advancing Translational Sciences/NIH (PI: Timothy Murphy, Medicine) for the project entitled, *Igniting Hope: Mobilizing Community Resources to Achieve Health Equity 2020*. The award provides funding for an annual community-based multidisciplinary conference, the goal of which is to continue the dialogue on developing a strategy to build a culture of hope, as the cornerstone of a plan to end health disparities among African Americans in Buffalo.



**Sue Ann Sisto**, Professor and Chair of Rehabilitation Science, is PI on a new award from the Community Foundation for Greater Buffalo/J. Warren Perry and Charles Donald Perry Memorial Fund for the project entitled, *Counseling and Support Groups for Persons Living with Spinal Cord Injury in the Community*. UB will partner with Motion Project Foundation (MPF) & MPF's Natalie Barnhard Center for Spinal Cord Injury Rehabilitation and Recovery to provide unique, first of its kind, community-based counseling and peer support services in WNY for people living with spinal cord injury.



**Gregory Wilding**, Professor and Chair of Biostatistics, is Co-I on five continuation awards. Two awards are from the National Institute on Aging/NIH. The first is titled, *The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses*, (PI: Elsa Bou Ghanem, Microbiology & Immunology). The project will continue to determine the role of polymorphonuclear leukocytes in the age-driven reduction in vaccine responses and increased susceptibility to streptococcus pneumoniae.

The second award, entitled *Age and Race Influences on Immunosuppression after Renal Transplant* (PI: Kathleen Tornatore, Pharmacy) will continue to seek to improve immunosuppression by creating novel dosing that integrates age, race and sex with cellular and clinical endpoints, pharmacokinetics, and pharmacogenomics to attain personalized medicine.

The third award is from the National Institute of Child Health & Human Development/NIH (PI: Patricia Logan-Greene, School of Social Work), and is titled, *Neglect, Poverty, and Family Services: A Longitudinal Perspective on Child Wellbeing*. This study utilizes data from the LONGSCAN study, a prospective study on child maltreatment, to examine the longitudinal effects of neglect (specifically the dimensions of failure to provide and lack of supervision) and its co-occurrence with poverty.

The fourth continuation award is from the National Institute of Dental & Craniofacial Research/NIH (PI: Michelle Kay, Oral Biology) for the project entitled, *The Role of Oral Spirochete Virulence Factors in the Impairment of Neutrophil Response*. The study seeks to understand how oral treponemese modulate neutrophil response leads to periodontal disease and the development of potentially active therapeutic molecules will lead to the improvement of oral and systemic health.

Dr. Wilding’s fifth continuation award is from the National Institute of Neurological Disorders and Stroke/NIH (PI: Ferdinand Schweser) and is titled, *Deep Gray Matter Iron and Disease Progression in Multiple Sclerosis*. The research is expected to determine a generalizable model of the evolution of imaging markers over time in patients relative to controls; cellular and molecular underpinnings of the imaging markers; and how imaging markers of iron are linked to neurodegeneration and injury in the white matter.

***In This Issue***

**In the News: Congratulations to the Following Awardees ..... 1**

**Grant Clinic ..... 4**

**NIH Funding Opportunities**

**Request for Applications (RFA) ..... 5**

**Program Announcements Reviews in an Institute (PAR) ..... 10**

**Individual Actions for Sustainability ..... 11**

## Grant Clinic

### GENERAL NOTICE

#### NOTICE OF INTENT TO PUBLISH

[NOT-CA-22-096](#), [NOT-CA-22-097](#) Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

[NOT-CA-22-098](#) NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

[NOT-NR-22-015](#) HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required)

#### NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-OD-22-148](#) – Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

[NOT-OD-22-150](#) – Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)

[NOT-OD-22-151](#) – Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)

[NOT-OD-22-153](#) – Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH)

The objective of the LRP programs is to recruit and retain highly qualified health professionals into their respective research careers. The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to \$50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career. Applications will be accepted beginning September 1 through November 17, 2022.

[NOT-AT-22-027](#) – Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes

This NOSI is being issued by the National Center for Complementary and Integrative Health (NCCIH) with participation from multiple NIH Institutes, Centers, and Offices (ICOs). It aims to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant as well as to broaden the focus on therapeutic benefits of minor cannabinoids and terpenes from pain to other symptoms, conditions and diseases that are of interests to other NIH ICOs. This Notice applies to due dates on or after October 5, 2022, and subsequent receipt dates through June 5, 2024.

[NOT-OD-22-135](#) – Stimulating Research to Understand and Address Hunger, Good and Nutrition Insecurity

This NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes and calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. This is an opportunity for future research to advance nutrition equity. This notice applies to due dates through November 29, 2024.

### [NOT-OD-22-178](#) – Increasing the Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan

Applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved are encouraged. Studies addressing efficacy, effectiveness, dissemination and implementation research, as well as studies seeking to understand and address barriers to screening are also encouraged. This notice applies to due dates through May 8, 2025.

### [NOT-OD-22-179](#) – Addressing Evidence Gaps in Screening

This notice is to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation as well as translational research aimed at filling identified knowledge gaps to expand the evidence base for evaluating the balance of benefits and harms for proposed preventive screenings. This notice applies to due dates through May 8, 2025.

### [NOT-MD-22-012](#) – Research on the Health of Sexual and Gender Minority (SGM) Populations

This Notice encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. This notice applies to due dates through August 8, 2025.

## NIH Funding Opportunities

### NIH Funding Opportunities: Request for Applications (RFA)

#### SEPTEMBER 2022 DUE DATES

[RFA-DA-23-041](#) (R01 Clinical Trial Required)

#### **HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL)**

NIDA seeks to support clinical trials that will evaluate multi-level interventions for patients who are using long-term opioid therapy to manage chronic pain for whom risks of continuing opioid therapy may outweigh the benefits of continued opioid use. Studies supported through this RFA must propose a study of individuals who have chronic pain and have been prescribed opioids for at least 90 days. Individuals should also exhibit behaviors suggesting that harms of continued opioid use may outweigh the benefits of continued opioid use.

**Application Due Date:** September 28, 2022

[RFA-DA-23-042](#) (U24 – Clinical Trial Optional)

#### **HEAL Initiative: Multilevel Interactions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center**

Applicants responding to this FOA should carefully review the companion FOA for the research projects ([RFA-DA-23-041](#)) to understand the full mission of this broader research program. The purpose of this companion FOA is to support clinical trials that will evaluate multi-level interventions for patients who are using long-term opioid therapy to manage chronic pain for whom risks of continuing opioid therapy may outweigh the benefits of continued opioid use. NIDA seeks studies for pharmacologic management with or without non-pharmacological approaches for managing chronic pain in those currently using long-term opioids. Interventions can target patients, health care providers (inclusive of pharmacists) or health care systems to reduce chronic pain and opioid-related risks and improve quality of life. **Application Due Date:** September 28, 2022

## OCTOBER 2022 DUE DATES

[RFA-NS-19-043](#) (K99/R00) Clinical Trial Not Allowed

[RFA-NS-19-044](#) (K99/R00) Independent Clinical Trial Required

### **BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity**

The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. **Application Due Date:** October 11, 2022

[RFA-DK-22-003](#) (R01, Clinical Trial Optional)

### **Promoting Organ and Tissue Donation Among Health Disparity Populations**

Proposed studies may include studying individual-level factors such as attitudes, beliefs, and behaviors towards organ and tissue donation, as well as the need for transplantation, among health disparity populations. In addition, proposed studies may examine the influence of SDoH on disparities in organ and tissue donation, including the impact of structural racism on donation. **Applications Due:** October 27, 2022

## NOVEMBER 2022 DUE DATES

[RFA-DA-23-048](#) (R61/R33 Clinical Trial Required)

### **HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers**

This FOA seeks to address the urgency and magnitude of the opioid crisis in populations that experience health disparities by developing and testing new or adapted interventions to prevent opioid misuse among patients served by community health centers (CHCs), and/or by developing and testing implementation strategies for screening and referral to preventive interventions for misuse of opioids and other substances among patients served by CHCs. **Application Due Date:** November 9, 2022

[RFA-MD-22-008](#) (R01, Clinical Trials Optional)

### **Understanding and Addressing Misinformation among Populations that Experience Health Disparities**

This initiative seeks to stimulate multi-level research (see [NIMHD Research Framework](#)) to understand and mitigate the harmful impacts of misinformation and disinformation among populations that experience health disparities and to inform public health practice. Examples include COVID-19, HIV/AIDS, STIs, vaccines, genetic testing, cancer, and tobacco use and cessation. **Application Due Date:** November 13, 2022

[RFA-DA-23-015](#) (R01, Clinical Trial Not Allowed)

### **Transformative Research on the Basic Mechanisms of Polysubstance Use in Addiction**

NIDA seeks to stimulate innovative research that will transform our understanding of the basic mechanisms that underlie polysubstance use in addiction. These studies will investigate novel neurobiological, pharmacological and/or behavioral mechanisms that drive the behavioral and pharmacological profiles observed following polysubstance use. **Application Due Date:** November 14, 2022

[RFA-AA-22-001](#) **Specialized Alcohol Research Centers** (P50, Clinical Trial Optional)

[RFA-AA-22-002](#) **Comprehensive Alcohol Research Centers** (P60, Clinical Trial Optional)

NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. The Centers are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research. **Application Due Date:** November 15, 2022

[RFA-DA-23-011](#) (UM1 – Clinical Trial Optional)

### **Registry of Medical Cannabis Use and Health Outcomes**

NIDA seeks applications to develop and maintain a medicinal cannabis use registry to assess the medical conditions reported as reasons for using medicinal cannabis, how and what products are being used, and the associated medical outcomes. The goal of this registry is to inform research, policy, and clinical recommendation practices on medicinal cannabis, associated conditions, and outcomes.

**Application Due Date:** November 16, 2022

**NCI's Informatics Technology for Cancer Research Program FOAs (Clinical Trial Optional):**

[RFA-CA-22-021](#) (R21) **Development of Innovative Informatics Methods and Algorithms**

[RFA-CA-22-022](#) (U01) **Early Stage Development of Informatics Technologies**

[RFA-CA-22-023](#) (U24) **Advanced Development of Informatics Technologies**

[RFA-CA-22-024](#) (U24) **Sustained Support for Informatics Technologies**

The program supports the development of critical tools and resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. **Application Due Date:** November 17, 2022

[RFA-DK-22-014](#) (U01 – Clinical Trial Required)

**Interventions that Address Structural Racism to Reduce Kidney Health Disparities**

This FOA invites applications for **Intervention Sites** that will work collaboratively with a Research Coordinating Center (RCC) (see [RFA-DK-22-015](#)) to develop and test meaningful interventions that aim to dismantle or mitigate the effects of structural racism to reduce kidney health disparities. **Application Due Date:** November 18, 2022

[RFA-DK-22-015](#) (U24 – Clinical Trial Not Allowed)

**Interventions that Address Structural Racism to Reduce Kidney Health Disparities – Research Coordinating Center**

This FOA invites applications for the Research Coordinating Center (RCC) that will lead, manage, and harmonize efforts for the Consortium. **Application Due Date:** November 18, 2022

[RFA-HD-23-008](#) (UG1 Clinical Trial Optional)

**NICHD Global Network for Women's and Children's Health Research: Research Units**

[RFA-HD-23-009](#) (U24 Clinical Trial Optional)

**NICHD Global Network for Women's and Children's Health Research: Data Coordinating Center**

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites U.S. institutions in partnership with research centers in low and middle-income countries to submit applications as Research Units (RUs) to participate in the Global Network for Women's and Children's Health Research. RUs will consist of U.S.-based research centers applying in partnership with research centers in low- and lower middle-income countries as defined by the World Bank. The RU grantees will become part of a cooperative network in scientific partnership with the NIH to conduct multi-center observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-constrained settings to address the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality. **Application Due Date:** November 30, 2022

**FEBRUARY 2023 DUE DATES**

[RFA-DA-23-045](#) (UG1 – Clinical Trial Not Allowed)

**HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats**

The goal of this FOA is to seek research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts. This FOA is part of the NIH's Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at <https://heal.nih.gov/>. **Application Due Date:** February 3, 2023

[RFA-DA-23-046](#) (RM1 – Clinical Trial Optional)

**HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On**

NIDA seeks applications for multi-project RM1 Opioid Use Disorder Quality Measurement and Management Research Centers (OUD-QM<sup>2</sup>RCs). OUD-QM<sup>2</sup>RCs will involve researchers and a partner with a deployed or in-development quality measurement strategy for opioid use disorder treatment that rigorous, scientific research could substantially advance. The ultimate goal is the creation of feasible, efficient quality measurement systems that provide meaningful information to help patients, families, and payors fairly

compare and select providers and to help clinicians and providers improve patient outcomes. **Application Due Date:** February 3, 2023

[RFA-DA-23-051](#) (R01 – Clinical Trials Optional)

**HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants**

Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. Research should be conducted within populations disproportionately affected by opioid use disorder, mental illness or death by suicide. Applications must involve populations disproportionately affected by opioid-related harms and take place within the U.S. and its territories. Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. **Application Due Date:** February 3, 2023

**MULTIPLE DUE DATES**

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

**Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research**

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

**Application Due Dates:** October 13, 2022, February 14, 2023, October 13, 2023, February 13, 2024

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

**HEAL Initiative: Translating Research to Practice to End the Overdose Crisis**

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to [RFA-DA-23-054](#), which solicits applications for which pilot data is available.

**Application Due Dates:** November 14, 2022; March 20, 2023; November 15, 2023; March 20, 2024

[RFA-HL-23-018](#) (R21)

**Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research**

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at [www.biolincc.nhlbi.nih.gov](http://www.biolincc.nhlbi.nih.gov).

**Applications Due:** October 19, 2022; June 20, 2023; October 19, 2023; June 20, 2024; October 21, 2024.

[RFA-MH-22-140](#) (R01); [RFA-MH-22-141](#) (R21) – Clinical Trial Not Allowed

**Understanding Suicide Risk and Protective Factors among Black Youth**

These FOAs encourage research that is designed to identify neurobiological, behavioral, social, and structural/systemic mechanisms underlying risk and protective factors for suicide among Black youth, with consideration for identification of novel targets for future development of prevention and intervention efforts.

**Application Due Dates:** October 19, 2022, and June 20, 2023

[RFA-EB-21-001](#) (R01, Clinical Trial Optional)

**Technology Development to Reduce Health Disparities**

This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. **Application**



**Due Dates:** January 26, 2023, and January 26, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

**NHLBI Outstanding Investigator Award (OIA)**

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

**NHLBI Emerging Investigator Award (EIA)**

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023, and February 15, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

**Accelerating the Pace of Drug Abuse Research Using Existing Data**

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. **Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

**High Priority HIV and Substance Use Research**

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

**NCI Outstanding Investigator Award**

The Outstanding Investigator Award (R35) is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. Applicants should describe a general research strategy, providing an overview of the broad research questions/scientific questions they plan to address, a general description of possible strategies, and a description of how their past scientific accomplishments will inform this research. Experimental details, extensive preliminary data, and specific aims should not be included unless critical to assessing the feasibility of the new avenues of research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

**Stimulants and HIV: Addressing Contemporary and Recurring Epidemics**

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

**Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)**

This FOA encourages SBIR grant applications directed towards commercialization, for the development of

novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

## **NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)**

[PAR-22-216](#) (R21 Clinical Trial Optional)

### **NCI Clinical and Translational Exploratory/Developmental Studies**

The purpose of this FOA is to promote innovative preclinical, early phase clinical, and correlative studies that are hypothesis-driven and based upon established basic cancer research discoveries. This FOA will support exploratory/developmental projects in the advancement of novel anti-cancer agents, diagnostic tools, correlative biomarker identification, clinical approaches in treatment, symptom management, and prevention of common or rare tumors, as well as research on cancer disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** July 2, 2025

[PAR-22-173](#) (R34, Clinical Trials Optional)

[PAR-22-174](#) (U34 Clinical Trials Optional)

### **Cancer Prevention and Control Clinical Trials Planning Grant Program**

The National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2025

[PAR-22-201](#) (P01 Clinical Trial Optional)

### **NIDA Program Project Grant Applications**

Program projects are expected to be broadly based investigative efforts with a clear, well-defined, and unifying goal or theme to establish the direction, objectives that address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse. A Program must be comprised of at least three inter-related research projects judged to be independently scientifically meritorious, complementary of one another, and demonstrate an essential element of unity and interdependence. **Application Due Dates:** Multiple Dates; see announcement.

**Expiration Date:** September 8, 2025

[PAR-22-210](#) (R01 Clinical Trial Optional)

### **Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants**

The FOA will also expand the scope and reach of projects supported through the Research to Action program (<https://www.niehs.nih.gov/research/supported/translational/rta/cfg/index.cfm>). The main objectives of this program remain the same as prior solicitations: 1) promote community engagement in environmental health research, 2) support multi-disciplinary research to collect and characterize information about environmental health concerns of significance to a community, and 3) stimulate research translation and dissemination to community members, public health professionals and/or policymakers to inform an action that will ultimately promote the reduction of exposure(s) and reduce the health impact from environmental stressors. To meet these stated objectives, applicants must propose CEnR projects that incorporate all three elements: community engagement, research, and public health action. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** September 8, 2025

[PAS-22-206](#) (K01 – Clinical Trial Required)

[PAS-22-207](#) (K23 – Clinical Trial Required)

### **HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment**

This FOA is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions

to the national opioid public health crisis. Applicants should focus on testing implementation strategies to improve the quality, effectiveness, availability, and affordability of substance use prevention or treatment services; to promote their integration and accessibility across a variety of settings (e.g., specialty care, primary care, schools, workplaces, and other nontraditional healthcare and community settings); and to promote equity in access and outcomes. **Application Due Dates:** Multiple Due Dates; see announcement.  
**Expiration Date:** November 13, 2025

## Individual Actions for Sustainability



Did you know....

A leaky faucet that fills a coffee cup in 10 minutes will waste an estimated 3,000 gallons of water per year. Be sure to keep a look out for any leaks in your home. If you do come across a leak, try home repairing yourself or contact a plumber. This can save you money and conserve water.

For more information on RAS services, visit our website at [sphhp.buffalo.edu/ras](https://sphhp.buffalo.edu/ras)